

Contents

Abstract	i-iii
Declaration by candidate	iv
Certificate of the Supervisor	v
Acknowledgement	vi-vii
Table of contents	viii-xi
List of figures	xii-xiii
List of tables	xiv
List of keywords	xv
List of abbreviations	xvi-xviii
Chapter 1 General Introduction and Review of Literature	1- 12
1.1 Snake venom proteins	1-2
1.2 Snake venom protein affecting haemostasis	2-3
1.3 Snake venom proteins affecting platelet aggregation	3-6
1.4 Cardiovascular diseases	6-8
1.5 Snake venom toxins and drugs discovery in light of cardiovascular diseases	8-9
1.6 Need for the proposed study	9-12
1.7 Objectives	12
Chapter 2 Materials and Methods	13-28
2.1 Materials	14-15
2.2 Methodology	15-28
2.2.1 Sodium dodecyl sulphate - polyacrylamide gel electrophoresis	15-16
2.2.2 Fractionation of crude <i>Daboia russelii</i> venom	16-17
2.2.3 LC-MS/MS analysis	17-18
2.2.3.1 In-solution digestion method	17-18
2.2.3.2 In-gel digestion method	18
2.2.4 Multiple sequence alignment and phylogenetic analysis	19
2.2.5 Biochemical characterizations	19-23
2.2.5.1 Coagulation assays	19-20

2.2.5.2	Phospholipase A ₂ activity	20
2.2.5.3	Caesinolytic activity	21
2.2.5.4	Haemolytic activity	21
2.2.5.5	Amidolytic activity	22
2.2.5.6	Inhibition of amidolytic activity of thrombin	22
2.2.5.7	Platelet aggregation assays	22-23
2.2.6	Effect of Daboxin P on platelet aggregation	23-25
2.2.6.1	Aggregation of PRP	23-24
2.2.6.2	Aggregation studies of K-562 cells	24-25
2.2.7	Effect of Daboxin P on thrombin mediated calcium mobilization	25
2.2.8	Alkylation of Daboxin P	25-26
2.2.9	Interaction studies of Daboxin P and thrombin	26-27
2.2.9.1	In-silico approach	26
2.2.9.2	Fluorescence emission spectroscopy	26
2.2.9.3	Affinity column chromatography	26-27
2.2.10	Inhibition of fibrinolytic activity of thrombin by Daboxin P	27
2.2.11	Neutralization of anti-platelet activity of Daboxin P with polyvalent antivenom	27
2.2.12	Statistical analysis	27
Chapter 3	Proteomics and partial characterization of crude <i>Daboia russelii</i> venom	28-76
3.1	Introduction	28-29
3.2	Results	29-68
3.2.1	Sodium dodecyl sulphate - polyacrylamide gel electrophoresis	29-30
3.2.2	Proteomic analysis of crude <i>Daboia russelii</i> venom	30-66
3.2.3	Partial characterization of crude <i>Daboia russelii</i> venom	66-68
3.2.3.1	Coagulation assays	66
3.2.3.2	Phospholipase A ₂ activity	66
3.2.3.3	Caesinolytic activity	68
3.2.3.4	Haemolytic activity	68
3.2.3.5	Platelet aggregation assay	68

3.3	Discussion	68-76
Chapter 4	Identification and characterization of anti-platelet protein from <i>Daboia russelii</i> venom	77-88
4.1	Introduction	77-78
4.2	Results	78-85
4.2.1	Fractionation of <i>Daboia russelii</i> venom by RP-HPLC	78-79
4.2.2	Screening of RP-HPLC fractions for anti-platelet activity	79-80
4.2.3	Platelet aggregation studies of anti-platelet fraction (P9)	80-82
4.2.3.1	Effect of P9 on platelet aggregation induced by various agonists	81
4.2.3.2	Dose dependent effect of P9 on platelet aggregation induced by collagen	82
4.2.3.3	Dose dependent effect of P9 on platelet aggregation induced by thrombin	82
4.2.4	Partial biochemical characterization of P9	82-84
4.2.4.1	SDS-PAGE	82
4.2.4.2	Coagulation assays	82
4.2.4.3	Phospholipase A ₂ activity	82
4.2.4.4	Haemolytic assays	82-83
4.2.4.5	Amidolytic activity	84
4.2.4.6	Inhibition of amidolytic activity of thrombin	84
4.2.5	Identification of P9	84-85
4.3	Discussion	86-88
Chapter 5	Exploring the mechanism of anti-platelet activity of Daboxin P	89-115
5.1	Introduction	89-90
5.2	Results	90-110
5.2.1	Gel filtration chromatography of crude <i>Daboia russelii</i> venom	90-91
5.2.2	SDS-PAGE of gel filtration fractions	91-92
5.2.3	Phospholipase A ₂ assay of the gel filtration fractions	92
5.2.4	Recalcification time of the gel filtration fractions	92
5.2.5	Reverse phase - high pressure liquid chromatography of GF10	94
5.2.6	Phospholipase A ₂ assay of the RP-HPLC fractions	94

5.2.7	Recalcification Time of the RP-HPLC fractions	94
5.2.8	Rechromatography of RP2	96
5.2.9	SDS-PAGE of rechromatography fraction	96
5.2.10	Peptide Mass Fingerprinting by LC-MS/MS	96-97
5.2.11	Effect of Daboxin P on platelet aggregation induced by different agonists	97-99
5.2.12	Effect of Daboxin P on platelet aggregation induced by collagen	100
5.2.13	Effect of Daboxin P on platelet aggregation induced by thrombin	101-102
5.2.14	Effect of Daboxin P on thrombin mediated calcium mobilization	103-104
5.2.15	Effect of alkylation of Daboxin P	104-105
5.2.16	Interaction studies of Daboxin P and thrombin	105-108
5.2.16.1	In-silico approach	105-107
5.2.16.2	Fluorescence emission spectroscopy	107
5.2.16.3	Affinity chromatography	108
5.2.17	Inhibition of amidolytic and fibrinolytic activities of thrombin by Daboxin P	108-109
5.2.18	Neutralization study of antiplatelet activity of Daboxin P with polyvalent antivenom	109-110
5.3	Discussion	110-115
Chapter 6	Conclusion and future prospects	116-117
6.1	Conclusion	116-117
6.2	Future prospects	117
	Bibliography	118-134
	List of publications	135
	Appendix	